Literature DB >> 9442494

PspA and PspC: their potential for use as pneumococcal vaccines.

D E Briles1, S K Hollingshead, E Swiatlo, A Brooks-Walter, A Szalai, A Virolainen, L S McDaniel, K A Benton, P White, K Prellner, A Hermansson, P C Aerts, H Van Dijk, M J Crain.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9442494     DOI： 10.1089/mdr.1997.3.401

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN： 1076-6294            Impact factor:   3.431


× No keyword cloud information.
  37 in total

1.  Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae.

Authors:  D E Briles; E Ades; J C Paton; J S Sampson; G M Carlone; R C Huebner; A Virolainen; E Swiatlo; S K Hollingshead
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

2.  Both family 1 and family 2 PspA proteins can inhibit complement deposition and confer virulence to a capsular serotype 3 strain of Streptococcus pneumoniae.

Authors:  Bing Ren; Alexander J Szalai; Orlanda Thomas; Susan K Hollingshead; David E Briles
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

3.  PspA protects Streptococcus pneumoniae from killing by apolactoferrin, and antibody to PspA enhances killing of pneumococci by apolactoferrin [corrected].

Authors:  Mirza Shaper; Susan K Hollingshead; William H Benjamin; David E Briles
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

4.  Immunization with PspA incorporated into a poly(ethylene oxide) matrix elicits protective immunity against Streptococcus pneumoniae.

Authors:  Quincy C Moore; LaShundra Johnson; Michael Repka; Larry S McDaniel
Journal:  Clin Vaccine Immunol       Date:  2007-04-25

5.  Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae.

Authors:  S K Hollingshead; R Becker; D E Briles
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

6.  Identification and characterization of a novel family of pneumococcal proteins that are protective against sepsis.

Authors:  J E Adamou; J H Heinrichs; A L Erwin; W Walsh; T Gayle; M Dormitzer; R Dagan; Y A Brewah; P Barren; R Lathigra; S Langermann; S Koenig; S Johnson
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

7.  Pneumococcal capsular polysaccharide preparations may contain non-C-polysaccharide contaminants that are immunogenic.

Authors:  X Yu; Y Sun; C Frasch; N Concepcion; M H Nahm
Journal:  Clin Diagn Lab Immunol       Date:  1999-07

8.  Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface.

Authors:  Bing Ren; Alexander J Szalai; Susan K Hollingshead; David E Briles
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

9.  A modified surface killing assay (MSKA) as a functional in vitro assay for identifying protective antibodies against pneumococcal surface protein A (PspA).

Authors:  Kristopher R Genschmer; Mary Ann Accavitti-Loper; David E Briles
Journal:  Vaccine       Date:  2013-11-06       Impact factor: 3.641

10.  Species-specific interaction of Streptococcus pneumoniae with human complement factor H.

Authors:  Ling Lu; Zhuo Ma; T Sakari Jokiranta; Adeline R Whitney; Frank R DeLeo; Jing-Ren Zhang
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.